Published in Clin Infect Dis on October 07, 2002
Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis (2004) 2.70
Predictors of early mortality in a cohort of human immunodeficiency virus type 1-infected african children. Pediatr Infect Dis J (2004) 2.30
Development of the Respiratory Index of Severity in Children (RISC) score among young children with respiratory infections in South Africa. PLoS One (2012) 1.21
Improved detection of Pneumocystis jirovecii in upper and lower respiratory tract specimens from children with suspected pneumocystis pneumonia using real-time PCR: a prospective study. BMC Infect Dis (2011) 0.99
Pneumocystis jirovecii pneumonia in tropical and low and middle income countries: a systematic review and meta-regression. PLoS One (2013) 0.91
Cost-effectiveness analysis of diagnostic options for pneumocystis pneumonia (PCP). PLoS One (2011) 0.89
Use of procalcitonin and C-reactive protein to evaluate vaccine efficacy against pneumonia. PLoS Med (2005) 0.88
Low prevalence of Pneumocystis jirovecii lung colonization in Ugandan HIV-infected patients hospitalized with non-Pneumocystis pneumonia. Diagn Microbiol Infect Dis (2011) 0.84
Humoral immune responses to Pneumocystis jirovecii antigens in HIV-infected and uninfected young children with pneumocystis pneumonia. PLoS One (2013) 0.77
Pneumocystis pneumonia in South African children diagnosed by molecular methods. BMC Res Notes (2014) 0.76
P. carinii pneumonia in African children and the ineffectiveness of TMP-SMX prophylaxis. Clin Infect Dis (2003) 0.75
Questions regarding the effectiveness of trimethoprim-sulfamethoxazole (cotrimoxazole) prophylaxis in African children. Clin Infect Dis (2003) 0.75
Clinical predictors of HIV infection in hospitalized children aged 2-18 months in Harare, Zimbabwe. Afr Health Sci (2012) 0.75
Rapid pneumococcal evolution in response to clinical interventions. Science (2011) 9.09
Antimicrobial resistance in developing countries. Part I: recent trends and current status. Lancet Infect Dis (2005) 5.58
Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet (2011) 5.43
International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med (2004) 4.75
Community-acquired Klebsiella pneumoniae bacteremia: global differences in clinical patterns. Emerg Infect Dis (2002) 4.08
An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis (2003) 3.93
Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis (2004) 3.75
Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis (2005) 3.72
Influenza vaccination of pregnant women and protection of their infants. N Engl J Med (2014) 3.68
Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med (2004) 3.49
A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med (2004) 3.49
The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Clin Infect Dis (2005) 2.81
Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis (2010) 2.50
Virulence characteristics of Klebsiella and clinical manifestations of K. pneumoniae bloodstream infections. Emerg Infect Dis (2007) 2.49
Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio (2011) 2.48
Density interactions among Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus in the nasopharynx of young Peruvian children. Pediatr Infect Dis J (2013) 2.47
Pneumococcal vaccination in developing countries. Lancet (2006) 2.45
Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus. Antimicrob Agents Chemother (2005) 2.14
Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect Dis (2008) 2.11
Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine (2007) 2.07
Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis J (2007) 2.06
Antimicrobial resistance in developing countries. Part II: strategies for containment. Lancet Infect Dis (2005) 2.05
Increased prevalence of pediatric pneumococcal serotypes in elderly adults. Clin Infect Dis (2005) 2.03
Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother (2006) 1.98
Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis (2009) 1.92
Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med (2014) 1.84
Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination. J Infect Dis (2009) 1.82
Increased risk of invasive bacterial infections in African people with sickle-cell disease: a systematic review and meta-analysis. Lancet Infect Dis (2010) 1.82
Maternal influenza immunization and reduced likelihood of prematurity and small for gestational age births: a retrospective cohort study. PLoS Med (2011) 1.82
Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistance. Emerg Infect Dis (2005) 1.74
Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin Infect Dis (2009) 1.69
Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin Infect Dis (2002) 1.66
Outpatient antibiotic prescribing and nonsusceptible Streptococcus pneumoniae in the United States, 1996-2003. Clin Infect Dis (2011) 1.63
Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine. Antimicrob Agents Chemother (2004) 1.53
Pneumococcal vaccines and flu preparedness. Science (2007) 1.50
The anticipated severity of a "1918-like" influenza pandemic in contemporary populations: the contribution of antibacterial interventions. PLoS One (2012) 1.47
Emergence of fluoroquinolone-resistant Streptococcus pneumoniae in a South African child in a tuberculosis treatment facility. Pediatr Infect Dis J (2003) 1.44
Pneumococcal capsular switching: a historical perspective. J Infect Dis (2012) 1.43
Serotype 6C is associated with penicillin-susceptible meningeal infections in human immunodeficiency virus (HIV)-infected adults among invasive pneumococcal isolates previously identified as serotype 6A in South Africa. Int J Antimicrob Agents (2008) 1.40
Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. J Infect Dis (2010) 1.39
World Health Organisation definition of "radiologically-confirmed pneumonia" may under-estimate the true public health value of conjugate pneumococcal vaccines. Vaccine (2006) 1.38
Emergence of Streptococcus pneumoniae with very-high-level resistance to penicillin. Antimicrob Agents Chemother (2004) 1.36
Role of Streptococcus pneumoniae in hospitalization for acute community-acquired pneumonia associated with culture-confirmed Mycobacterium tuberculosis in children: a pneumococcal conjugate vaccine probe study. Pediatr Infect Dis J (2010) 1.33
Influence of bacterial interactions on pneumococcal colonization of the nasopharynx. Trends Microbiol (2012) 1.33
Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J (2005) 1.31
The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J Infect Dis (2006) 1.30
A framework for global surveillance of antibiotic resistance. Drug Resist Updat (2011) 1.29
Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children. Clin Infect Dis (2012) 1.26
Live attenuated influenza vaccine enhances colonization of Streptococcus pneumoniae and Staphylococcus aureus in mice. MBio (2014) 1.26
Global epidemiology of invasive meningococcal disease. Popul Health Metr (2013) 1.25
Epidemiology of Group B Streptococcus in developing countries. Vaccine (2013) 1.24
Communicating trends in resistance using a drug resistance index. BMJ Open (2011) 1.23
Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine (2010) 1.23
Lower respiratory tract infections associated with influenza A and B viruses in an area with a high prevalence of pediatric human immunodeficiency type 1 infection. Pediatr Infect Dis J (2002) 1.22
Development of the Respiratory Index of Severity in Children (RISC) score among young children with respiratory infections in South Africa. PLoS One (2012) 1.21
Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection. Pediatr Infect Dis J (2002) 1.19
The impact of antiretroviral treatment on the burden of invasive pneumococcal disease in South African children: a time series analysis. AIDS (2011) 1.19
Neisseria meningitidis intermediately resistant to penicillin and causing invasive disease in South Africa in 2001 to 2005. J Clin Microbiol (2008) 1.19
Analysis of penicillin-binding protein genes of clinical isolates of Streptococcus pneumoniae with reduced susceptibility to amoxicillin. Antimicrob Agents Chemother (2002) 1.16
Seasonality, incidence, and repeat human metapneumovirus lower respiratory tract infections in an area with a high prevalence of human immunodeficiency virus type-1 infection. Pediatr Infect Dis J (2007) 1.16
In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother (2008) 1.16
Human metapneumovirus genetic variability, South Africa. Emerg Infect Dis (2005) 1.15
Human metapneumovirus-associated lower respiratory tract infections among hospitalized human immunodeficiency virus type 1 (HIV-1)-infected and HIV-1-uninfected African infants. Clin Infect Dis (2003) 1.14
Bacterial pathogens and death during the 1918 influenza pandemic. N Engl J Med (2009) 1.14
Antibiotic resistance and serotype distribution of Streptococcus pneumoniae colonizing rural Malawian children. Pediatr Infect Dis J (2003) 1.14
Efficacy of whole-cell killed bacterial vaccines in preventing pneumonia and death during the 1918 influenza pandemic. J Infect Dis (2010) 1.11
Increased incidence of meningococcal disease in HIV-infected individuals associated with higher case-fatality ratios in South Africa. AIDS (2010) 1.11
Pneumococcal coinfection with human metapneumovirus. J Infect Dis (2006) 1.09
Fluoroquinolone-resistant Streptococcus pneumoniae. Emerg Infect Dis (2006) 1.08
Novel role for the Streptococcus pneumoniae toxin pneumolysin in the assembly of biofilms. MBio (2013) 1.08
Persistent high burden of invasive pneumococcal disease in South African HIV-infected adults in the era of an antiretroviral treatment program. PLoS One (2011) 1.08
Recommendations for treatment of childhood non-severe pneumonia. Lancet Infect Dis (2009) 1.07
The relationship between pneumococcal serotypes and antibiotic resistance. Vaccine (2012) 1.07
The future of pneumococcal disease prevention. Vaccine (2011) 1.06
Immunogenicity and effectiveness of Haemophilus influenzae type b conjugate vaccine in HIV infected and uninfected African children. Vaccine (2005) 1.06
Fluoroquinolone resistance among clinical isolates of Streptococcus pneumoniae belonging to international multiresistant clones. J Antimicrob Chemother (2002) 1.05
The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children? Clin Infect Dis (2002) 1.04
Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: South Africa, 2003-2008. Vaccine (2013) 1.04
Susceptibility of Yersinia pestis to novel and conventional antimicrobial agents. J Antimicrob Chemother (2003) 1.03
Variable recombination dynamics during the emergence, transmission and 'disarming' of a multidrug-resistant pneumococcal clone. BMC Biol (2014) 1.03
Vaccines as tools against resistance: the example of pneumococcal conjugate vaccine. Semin Pediatr Infect Dis (2004) 1.02
The LuxS-dependent quorum-sensing system regulates early biofilm formation by Streptococcus pneumoniae strain D39. Infect Immun (2011) 1.02
Quorum-sensing systems LuxS/autoinducer 2 and Com regulate Streptococcus pneumoniae biofilms in a bioreactor with living cultures of human respiratory cells. Infect Immun (2013) 1.01
The multidrug-resistant PMEN1 pneumococcus is a paradigm for genetic success. Genome Biol (2012) 1.01
Usefulness of C-reactive protein to define pneumococcal conjugate vaccine efficacy in the prevention of pneumonia. Pediatr Infect Dis J (2006) 1.01
Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States. Vaccine (2009) 1.00
Conserved mutations in the pneumococcal bacteriocin transporter gene, blpA, result in a complex population consisting of producers and cheaters. MBio (2011) 1.00
Time from illness onset to death, 1918 influenza and pneumococcal pneumonia. Emerg Infect Dis (2009) 1.00